Zhitong Finance App News, Shandong Xinhua Pharmaceutical Co., Ltd. (00719) issued an announcement. Recently, the company received the “Drug Registration Certificate” for ketorolac and tromethotriol injections approved and issued by the State Drug Administration.

This product is suitable for short-term treatment of moderate to severe acute pain requiring opioid level analgesia in adults (no more than 5 days), and is usually used for post-operative analgesia. This product belongs to category B of the “National Catalogue of Drugs for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2025)”. According to relevant statistics, sales of ketorolac and tromethotriol injections in public medical institutions in China will be approximately RMB 230 million in 2025.

Xinhua Pharmaceuticals' ketorolac trometametriol injection obtained a drug registration certificate in November 2026, which is conducive to enriching the company's analgesic product line and improving the company's market competitiveness.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.